Several new therapies are revolutionizing glucose management, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide emerging as potential options. Retatrutide, a dual GIP and GLP-1 target stimulant, shows substantial body mass decrease and enhanced glycemic regulation. Cagrillintide, one GLP-1 activator, is presently in clinical assessments